Direxion Daily LLY Bear 1X Shares

Eli Lilly's Acquisition of Ventyx Biosciences Receives Early Termination Notice

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

IBBQ

ELIS

ELIL

LLYX

The U.S. Supreme Court denied Eli Lilly's petition, finalizing a $220M judgment for defrauding the Medicaid Drug Rebate Program. This marks a significant victory for whistleblower Ronald J. Streck and his legal team after a 12-year legal battle. The case, initiated in 2014, revealed that Eli Lilly failed to pay required Medicaid rebates following price increases. This decision upholds a unanimous jury verdict and highlights the success of False Claims Act litigation.

prnewswire

Eli Lilly

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

Direxion Daily LLY Bull 2X Shares

Proshares Ultra Nasdaq Biotech

VG Health

iShares US Pharma

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Defiance Daily Target 2X Long LLY ETF

ALPS Medical Breakthrough

07:27 ETWMHW Secures Victory; U.S. Supreme Court Denies Eli Lilly's Petition for Certiorari, Finalizing $220M+ False Claims Act Judgment

Trump purchased up to $680,000 in Eli Lilly stock amid favorable federal policies for its obesity drugs. Legal ethicists express concerns about the timing potentially undermining public trust, although Trump's team claims the trades are independently managed. This move reflects a broader shift from bonds to numerous stock trades linked to administration policies.

Trump purchased Eli Lilly stock as policies favored its drugs

NVDQ

Today's market shows mixed results across sectors. Tech stocks see volatility with Oracle down 3.60% and Nvidia falling 1.22%, while Google rises 2.28%. The healthcare sector faces pressure, with Eli Lilly down 1.58%. Financials are mixed, with Bank of America up 1.64% but American Express down 0.58%. Investors are advised to diversify portfolios to navigate sector challenges and capitalize on emerging trends.

Investinglive

T-Rex 2X Inverse NVIDIA Daily Target ETF

YieldMax NVDA Option Income Strategy ETF

T-Rex 2X Long NVIDIA Daily Target ETF

Defiance Daily Target 2X Long ORCL ETF

Direxion Daily GOOGL Bull 2X Shares

iShares Global Healthcare

Roundhill GOOGL WeeklyPay ETF

Microsoft

Oracle

NVIDIA

Micron Tech

Alphabet

Alphabet - C

Amazon

CVS Health

Bank of America

Visa

American Express

ORACLE CORP DEPOSITARY SH REP 1/2000TH PFD SER D

NVIDIA Corporation

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Tech stocks rally while healthcare faces pressure: A closer look at today's market

LLYZ

LABD

Eli Lilly was among the pharmaceutical companies denied certiorari by the Supreme Court, which rejected multiple appeals related to healthcare and commercial cases. This decision diminishes the chances of immediate Supreme Court intervention in these matters. Following the news, Eli Lilly's shares fell by 2.2% to $985.25.

fidelity

Defiance Daily Target 2X Short LLY ETF

Direxion S&P Biotech Bear 3X

Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals

Eli Lilly (LLY) has emerged as a leader in the obesity drug market with its GLP-1 based products, Mounjaro and Zepbound, significantly boosting its stock. However, concerns about policy uncertainties and elevated expectations suggest that the market may have already priced in much of the growth potential. While demand for obesity treatments remains strong, potential risks could lead to volatility, prompting a neutral stance on LLY.

Tip Ranks

Eli Lilly (LLY) Is the Face of the Obesity Boom. Has the Market Already Priced It In?

Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference | LLY Stock News

StockTitan

AllianceBernstein

Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference | LLY Stock News

Representative Byron Donalds (Republican-Florida) purchased shares of Eli Lilly and Company (NYSE: LLY) valued between $1,001 and $15,000 on April 2nd, as disclosed in a filing on May 13th. The stock has seen a recent decline, trading down $1.51 to $1,005.20. Eli Lilly reported strong quarterly earnings, beating estimates with $8.55 EPS and $19.80 billion in revenue, and declared a quarterly dividend of $1.73 per share.

Market Beat

Novo Nordisk AS

Hims & Hers Health

Chipotle Mexican Grill

Intuit

Marvell Tech

Netflix

Trade Desk

Paypal

Viking Therap

Daiwa Securities Group Inc.

Barclays

Eli Lilly and Company (NYSE:LLY) Stock Acquired Rep. Byron Donalds

Eli Lilly has committed $50 million over six years to UNICEF USA to enhance the prevention and management of noncommunicable diseases (NCDs) among children. This significant increase follows previous donations totaling $20.9 million in the past five years. The funds will help UNICEF reach 30 million young people in 21 low- and middle-income countries, focusing on managing NCDs and supporting children with obesity. This commitment comes amid financial pressures on UNICEF, which is cutting costs and relocating staff due to funding rescissions by U.S. lawmakers.

Fiercepharma

Eli Lilly delivers $50M boost to UNICEF’s pediatric health push

In the latest update, it has been reported that the economic growth rate for the second quarter of this year has surpassed expectations, reaching an impressive 6.5%. This robust performance has exceeded the projected 6.3% growth rate, indicating a strong recovery in the economy. Additionally, the latest unemployment figures show a decrease to 5.4%, down from the previous 5.9%. These positive indicators suggest a promising path towards economic stability and recovery in the coming months.

Unusual Whales

Elis grows network with acquisition of Wäsche Perle in Switzerland, boosting presence in the region.

Eli Lilly (NYSE: LLY) has released four-year data for Omvoh (mirikizumab) in ulcerative colitis, demonstrating durable disease clearance and adding long-term evidence of effectiveness and safety. The stock is currently trading at $966.99, up 28.9% over the past year. The new data may influence investor perceptions of Omvoh's role in the treatment landscape and the company's immunology portfolio. Analysts note the stock is trading 20% below the consensus target and 31.1% below estimated fair value, indicating potential undervaluation. Key considerations include Omvoh's uptake and payer coverage.

Simplywall

Eli Lilly Ulcerative Colitis Data Highlights Omvoh Durability And Valuation Upside

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

Direxion Daily LLY Bear 1X Shares(ELIS.US)

07:27 ETWMHW Secures Victory; U.S. Supreme Court Denies Eli Lilly's Petition for Certiorari, Finalizing $220M+ False Claims Act Judgment

Trump purchased Eli Lilly stock as policies favored its drugs

Tech stocks rally while healthcare faces pressure: A closer look at today's market

Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals

Eli Lilly (LLY) Is the Face of the Obesity Boom. Has the Market Already Priced It In?